Roche buys cervical cancer specialist mtm laboratories


Basel – Swiss pharma and diagnostics major Roche AG has agreed to buy privately-held Heidelberg-based mtm laboratories AG, a specialist for kits detecting pre-stages of cervical cancer, for up to EUR190m. Under the terms of the agreement, Roche will pay mtm’s shareholders an upfront payment of approximately EUR130m, as well as up to approximately EUR60m upon reaching certain performance-related milestones. The German company sells an in vitro diagnostic kit for the diagnosis of CIN lesions that occur before the development of cervical cancer. In the future, mtm will become part of Roche’s Tissue Diagnostics business unit, which markets PCR-based tests for the detection of the human papilloma viruses that trigger the development of cervical cancer. mtm’s test detects two markers for cell proliferation, p16INK4a und Ki-67, that can be stained with the kit. The diagnostic value of the test was proven in three European studies with more than 32,000 samples. Usually, cervical cancer is detected by a pap smear test, which is cheap but not very sensitive. mtm has proven that tests from its Cintech family can add a higher diagnostic sensitivity to the smear-test gold standard.



Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...



London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...



Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...



After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...



The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...



Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...



Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....



Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2015 BIOCOM



All Events


Product of the week


Current issue

All issues